Literature DB >> 9924240

Patient-controlled interscalene analgesia with ropivacaine after major shoulder surgery: PCIA vs PCA.

A Borgeat1, E Tewes, N Biasca, C Gerber.   

Abstract

We have compared the efficacy of patient-controlled interscalene analgesia (PCIA) using ropivacaine with patient-controlled analgesia (PCA) using nicomorphine in 60 patients (n = 30 in each group), in a prospective, randomized study. In both groups, all patients received interscalene block with 0.75% ropivacaine before induction of anaesthesia. Six hours after interscalene block, patients in group PCIA received continuous infusion of 0.2% ropivacaine at a rate of 5 ml h-1 with a bolus dose of 3 or 4 ml and a lockout time of 20 min; patients in group PCA received continuous infusion of nicomorphine 0.5 mg h-1 and a bolus dose of 2 or 3 mg with a lockout time of 20 min. Control of pain was significantly better from 12 to 48 h after operation (except at 42 h) in group PCIA. Nausea and pruritus occurred significantly more frequently in group PCA. Patient satisfaction was greater in group PCIA. We conclude that the use of 0.2% ropivacaine using PCIA was an efficient way of managing pain after major shoulder surgery and compared favourably with PCA nicomorphine in terms of pain relief, side effects and patient satisfaction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9924240     DOI: 10.1093/bja/81.4.603

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  19 in total

Review 1.  Ropivacaine: a review of its use in regional anaesthesia and acute pain management.

Authors:  Dene Simpson; Monique P Curran; Vicki Oldfield; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  [Intrathecal misplacement of an interscalene plexus catheter].

Authors:  M Walter; P Rogalla; C Spies; W J Kox; T Volk
Journal:  Anaesthesist       Date:  2005-03       Impact factor: 1.041

Review 3.  [The value of regional and general anaesthesia in orthopaedic surgery].

Authors:  O Vicent; M Hübler; S Kirschner; T Koch
Journal:  Orthopade       Date:  2007-06       Impact factor: 1.087

4.  Primary payer status is associated with the use of nerve block placement for ambulatory orthopedic surgery.

Authors:  Patrick J Tighe; Meghan Brennan; Michael Moser; Andre P Boezaart; Azra Bihorac
Journal:  Reg Anesth Pain Med       Date:  2012 May-Jun       Impact factor: 6.288

5.  [Cost minimization analysis in postoperative pain management : economic efficiency and effectiveness of two infusion pump systems].

Authors:  A-K Bräscher; J Blunk; S Söhle; R E Feldmann; M Bauer; J Benrath
Journal:  Anaesthesist       Date:  2014-10       Impact factor: 1.041

Review 6.  Patient-controlled analgesia in the management of postoperative pain.

Authors:  Mona Momeni; Manuela Crucitti; Marc De Kock
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Ropivacaine: an update of its use in regional anaesthesia.

Authors:  K J McClellan; D Faulds
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

8.  A clinical comparison of continuous interscalene brachial plexus block with different basal infusion rates of 0.2% ropivacaine for shoulder surgery.

Authors:  Chun Woo Yang; Sung Mee Jung; Hee Uk Kwon; Choon-Kyu Cho; Jin Woong Yi; Chul Woung Kim; Jong-Kwon Jung; Young Mi An
Journal:  Korean J Anesthesiol       Date:  2010-07-21

Review 9.  Continuous interscalene brachial plexus block versus parenteral analgesia for postoperative pain relief after major shoulder surgery.

Authors:  Hameed Ullah; Khalid Samad; Fauzia A Khan
Journal:  Cochrane Database Syst Rev       Date:  2014-02-04

10.  [Differences of analgesic efficacy and complication rates between ultrasound and nervestimulator guided peripheral nerve catheters : Database analysis on patient-relevant target parameters].

Authors:  A Schnabel; B Middendorf; M G Boschin; A Gottschalk; H Van Aken; P K Zahn; E M Pogatzki-Zahn
Journal:  Anaesthesist       Date:  2014-09-18       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.